JP2021512910A5 - - Google Patents

Info

Publication number
JP2021512910A5
JP2021512910A5 JP2020542665A JP2020542665A JP2021512910A5 JP 2021512910 A5 JP2021512910 A5 JP 2021512910A5 JP 2020542665 A JP2020542665 A JP 2020542665A JP 2020542665 A JP2020542665 A JP 2020542665A JP 2021512910 A5 JP2021512910 A5 JP 2021512910A5
Authority
JP
Japan
Prior art keywords
cocrystal
powder
proline
ray diffractogram
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2020542665A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512910A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/016304 external-priority patent/WO2019156907A1/en
Publication of JP2021512910A publication Critical patent/JP2021512910A/ja
Publication of JP2021512910A5 publication Critical patent/JP2021512910A5/ja
Priority to JP2023173340A priority Critical patent/JP2024001167A/ja
Priority to JP2025178611A priority patent/JP2026012851A/ja
Ceased legal-status Critical Current

Links

JP2020542665A 2018-02-07 2019-02-01 ノボビオシン類似体とプロリンとの共結晶形態 Ceased JP2021512910A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023173340A JP2024001167A (ja) 2018-02-07 2023-10-05 ノボビオシン類似体とプロリンとの共結晶形態
JP2025178611A JP2026012851A (ja) 2018-02-07 2025-10-23 ノボビオシン類似体とプロリンとの共結晶形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862627570P 2018-02-07 2018-02-07
US62/627,570 2018-02-07
PCT/US2019/016304 WO2019156907A1 (en) 2018-02-07 2019-02-01 Co-crystal forms of a novobiocin analog and proline

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2023173340A Division JP2024001167A (ja) 2018-02-07 2023-10-05 ノボビオシン類似体とプロリンとの共結晶形態
JP2025178611A Division JP2026012851A (ja) 2018-02-07 2025-10-23 ノボビオシン類似体とプロリンとの共結晶形態

Publications (2)

Publication Number Publication Date
JP2021512910A JP2021512910A (ja) 2021-05-20
JP2021512910A5 true JP2021512910A5 (cg-RX-API-DMAC7.html) 2022-02-04

Family

ID=65444361

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020542665A Ceased JP2021512910A (ja) 2018-02-07 2019-02-01 ノボビオシン類似体とプロリンとの共結晶形態
JP2023173340A Withdrawn JP2024001167A (ja) 2018-02-07 2023-10-05 ノボビオシン類似体とプロリンとの共結晶形態
JP2025178611A Pending JP2026012851A (ja) 2018-02-07 2025-10-23 ノボビオシン類似体とプロリンとの共結晶形態

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023173340A Withdrawn JP2024001167A (ja) 2018-02-07 2023-10-05 ノボビオシン類似体とプロリンとの共結晶形態
JP2025178611A Pending JP2026012851A (ja) 2018-02-07 2025-10-23 ノボビオシン類似体とプロリンとの共結晶形態

Country Status (19)

Country Link
US (3) US10717755B2 (cg-RX-API-DMAC7.html)
EP (1) EP3749675B1 (cg-RX-API-DMAC7.html)
JP (3) JP2021512910A (cg-RX-API-DMAC7.html)
KR (2) KR102718111B1 (cg-RX-API-DMAC7.html)
CN (2) CN112020506B (cg-RX-API-DMAC7.html)
AR (1) AR114245A1 (cg-RX-API-DMAC7.html)
AU (3) AU2019217821B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020016205A2 (cg-RX-API-DMAC7.html)
CA (2) CA3090646C (cg-RX-API-DMAC7.html)
CL (2) CL2020002051A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020009761A2 (cg-RX-API-DMAC7.html)
EA (1) EA202091885A1 (cg-RX-API-DMAC7.html)
IL (2) IL315865A (cg-RX-API-DMAC7.html)
MX (2) MX2020008326A (cg-RX-API-DMAC7.html)
MY (1) MY209803A (cg-RX-API-DMAC7.html)
PE (1) PE20211446A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202007530XA (cg-RX-API-DMAC7.html)
TW (3) TWI868593B (cg-RX-API-DMAC7.html)
WO (1) WO2019156907A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020016205A2 (pt) 2018-02-07 2020-12-15 Reata Pharmaceuticals, Inc. Formas cocristalinas de prolina e de análogo de novobiocina
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
CN115181146B (zh) * 2021-04-02 2024-06-04 浙江普洛家园药业有限公司 一种新生霉素的提取工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013006651A2 (pt) 2010-09-23 2017-07-18 Nuformix Ltd composição e cocristal de aprepitante l-prolina
TWI542596B (zh) * 2011-05-09 2016-07-21 健生藥品公司 (2s,3r,4r,5s,6r)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羥甲基)四氫-2h-哌喃-3,4,5-三醇之l-脯胺酸及檸檬酸共晶體
CN108640910A (zh) * 2011-11-25 2018-10-12 诺弗米克斯技术有限公司 阿瑞吡坦l-脯氨酸溶剂化物-组合物和共晶体
EP2602249B1 (en) * 2011-12-06 2015-08-12 F.I.S. Fabbrica Italiana Sintetici S.p.A. Synthesis of rosuvastatin by means of co-crystals
BR112014019704B1 (pt) * 2012-02-09 2022-05-31 University Of Kansas Compostos inibidores de hsp90 c-terminais, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou prevenção de um distúrbio neurodegenerativo
US9556216B2 (en) * 2012-08-31 2017-01-31 Novartis Ag 2′-Ethynyl nucleoside derivatives for treatment of viral infections
TW201512201A (zh) * 2013-03-14 2015-04-01 Forum Pharmaceuticals Inc 化合物的多晶型及鹽類
CA3289739A1 (en) 2014-06-24 2025-11-29 The University Of Kansas Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers
PT3202772T (pt) * 2014-09-30 2020-11-20 Jiangsu Hengrui Medicine Co Cristal de um complexo de l-prolina/inibidor do cotransportador de sódio-glicose 2
BR112020016205A2 (pt) 2018-02-07 2020-12-15 Reata Pharmaceuticals, Inc. Formas cocristalinas de prolina e de análogo de novobiocina

Similar Documents

Publication Publication Date Title
EP1670757B1 (en) Pyrrole and pyrazole derivatives as potentiators of glutamate receptors
TWI299991B (en) Cetp inhibitors
EP3022202B1 (en) Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
KR101424013B1 (ko) 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산의 결정형과 그의 제조방법
US20210052585A1 (en) Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same
TW201418218A (zh) 部份飽和的含氮雜環化合物
KR20220054293A (ko) Isoqc 및/또는 qc 효소의 억제제로서 n-치환된-3,4-(융합된 5-환)-5-페닐-피롤리딘-2-온 화합물
JP2023541434A5 (cg-RX-API-DMAC7.html)
WO2017048962A1 (en) Hepatitis b core protein modulators
EP3612520B1 (en) Isoxazole derivatives as nuclear receptor agonists and uses thereof
TW201018460A (en) Organic compounds and their uses
EP2736332A1 (en) Compounds and methods
US20100210693A1 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
TW201536743A (zh) Mdm2抑制劑之製備方法及結晶型
CA2546142A1 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
JP6208212B2 (ja) 呼吸器疾患用薬
AU2003210916B2 (en) Opioid receptor active 4-(3-hydroxyphenyl) or 4-(3-alkoxyphenyl)-1,2,4-triazole compounds
US20080015237A1 (en) New compounds i/418
US11155537B2 (en) Crystal of benzofuran derivative free base and preparation method
JP2021536505A5 (cg-RX-API-DMAC7.html)
US20140288040A1 (en) Substituted benzylamine compounds, their use in medicine, and in particular the treatment of hepatitis c virus (hcv) infection
TW200404802A (en) Xanthine phosphodiesterase V inhibitor polymorphs
JP7158464B2 (ja) カリウムチャネル阻害剤としての置換ベンゾイミダゾール
AU2020325517B2 (en) Alcohol derivatives as KV7 potassium channel openers
US11447470B2 (en) Pyrimidinone-containing compound, preparation method thereof, pharmaceutical composition and application thereof